When cancer spreads to the brain, treatment options fall off. Most of the drugs designed to target metastases do not cross the blood-brain barrier or are ineffective at treating brain metastases.
“Understanding how cancer cells thrive or fail in the brain niche could help us develop new treatments targeting these molecular processes,” said Sofia Merajver, M.D., Ph.D., the Greater Good Breast Cancer Research Professor at the University of Michigan Rogel Cancer Center.
To understand the molecular processes that influence how cancer cells pass through the blood-brain barrier, Merajver and colleagues used two microfluidic chips that mapped cancer cell migration to the brain and looked at what was happening in the blood-brain niche. Results are published in the journal Advanced NanoBiomed Research.
Using breast cancer cell lines, they found that Dkk-1, a cytokine released by the astrocytes, triggers the cancer cells to migrate. Dkk-1 is known to play a role in in Wnt signaling, a key signaling pathway linked to cancer progression.
“Crosstalk between brain niche cells and cancer cells allows invading cancer cells to permeate the blood-brain barrier. Reducing Dkk-1 levels near invading tumor cells might disrupt this crosstalk and prevent brain metastases,” said corresponding author Christopher R. Oliver, Ph.D., a post-doctoral fellow in the Merajver Lab.
Read the original article on University of Michigan.